The results of molecular docking and MD simulation analyses further revealed the inhibitory potentiality of IR3G and its aglycone IR against the PD-related neurogenic targets (human MAO-B, AChE, and PLK2). The gene discussed is MAOB; the disease is Parkinson disease.